Novartis announced in a press statement today that it has made the first batch of vaccine against the A (H1N1) influenza virus causing the swine flu pandemic. The Swiss-based pharmaceutical company said that it had made 10 liters of vaccine that it will use in pre-clinical studies and maybe early clinical trials. The company uses cells to grow the virus for the vaccine and claims that this “shows significant time saving” over traditional production with eggs. Thirty governments have “made requests” to the company for vaccine ingredients. If all goes well, the company expects to receive regulatory approval of its vaccine in the fall.
Read our COVID-19 research and news.